UChicago Medicine 7th Annual Updates from ASH 2021 Practice Changing Abstracts 2022
Format:17 videos, size: 1.17 GB
Course Audience: hematologists, pathologists, medical oncologists
Overview:
Our goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, this activity will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths. Our overarching goal is to keep all healthcare professionals involved in the care of patients with hematologic malignancies to stay abreast of the latest scientific updates, innovative ideas, and timeliest issues related to their care. This conference will provide the target audience with information that can help improve patient management and care strategies. Participants will discuss with content experts rapidly evolving developments, discover new treatments for patients, and improve overall practice paradigms. We will educate and empower community-based oncologists on best practices for treating hematologic cancers and inform them of the indicators for when to refer a patient for tertiary level care.Target Audience
This activity is designed for primary care physicians, hematologists, pathologists, medical oncologists, resident and fellow trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to the treatment of hematologic cancers.Learning Objectives
At the conclusion of this activity, participants will be able to:
- Illustrate how cutting-edge data presented at the 2021 Annual Meeting of the American Society of Hematology (ASH) can apply to clinical practice, addressing best practices and guidelines;
- State the emerging treatment strategies for patients with low- and high-risk myeloid malignancies;
- Discuss the optimal patient selection, timing, and regimen for transplant;
- Evaluate clinical trial data in the context of cellular CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards;
- Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines;
- Identify methods for integrating therapeutic advances such as CAR-T therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) into practice for myeloma patient care;
- Describe the pathogenesis, diagnostic evaluation and therapeutic modalities available for common benign hematologic diseases and COVID-associated hematologic diseases.
Advances in Cellular Therapy and Transplantation (Video TS Format)
ASH Review on Immunotherapies in Leukemia (Video TS Format)ASH Review Updates in Nonmalignant Hematology (Video TS Format)Myeloma Highlights of ASH 2021 (Video TS Format)Post-ASH 2021 Cellular Therapy Continuum Initial Consult to Post-Treatment Follow-Up (Video TS Format)Post-ASH 2021 Faces of Cellular Therapy Nursing Inpatient Phase (Video TS Format)Post-ASH 2021 Nursing Clinical Trials It’s Not Trial By Fire (Video TS Format)Post-ASH Case Discussion 59 yo Male With Blurry Vision and Developed Myeloma (Video TS Format)Post-ASH Case Discussion 61 yo Female With Progressive Fatigue Who Developed AML (Video TS Format)Post-ASH Case Discussion 61 yo Male With Right Neck Swelling Who Developed DLBCL (Video TS Format)Post-ASH Case-Based Clinical Trial Considerations Cellular Therapy for Acute Leukemia (Video TS Format)Post-ASH Case-Based Clinical Trial Considerations Follicular Lymphoma (Video TS Format)Post-ASH Case-Based Review of Multiple Myeloma Clinical Trial Considerations (Video TS Format)Post-ASH Evolving Standards of Care in Lymphoma (Video TS Format)Post-ASH New Strategies in Myeloid Malignancies AML Treatment (Video TS Format)Post-ASH Review Case-Based Clinical Trial Considerations ALL AML (Video TS Format)Practice-Changing and Promising New Treatments in Myeloma (Video TS Format)